TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model.

ABSTRACT:

Background

Ewing sarcoma (EwS) is an aggressive and highly metastatic bone and soft tissue tumor in pediatric patients and young adults. Cure rates are low when patients present with metastatic or relapsed disease. Therefore, innovative therapy approaches are urgently needed. Cellular- and oncolytic virus-based immunotherapies are on the rise for solid cancers.

Methods

Here, we assess the combination of EwS tumor-associated antigen CHM1³¹⁹-specific TCR-transgenic CD8⁺ T cells and the YB-1-driven (i.e. E1A13S-deleted) oncolytic adenovirus XVir-N-31 in vitro and in a xenograft mouse model for antitumor activity and immunostimulatory properties.

Results

In vitro both approaches specifically kill EwS cell lines in a synergistic manner o

SUBMITTER: Schober SJ 

PROVIDER: S-EPMC10839048 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature